PGR and breast cancer: Triple-negative (TN) BC accounts for approximately 10–15% of all diagnosed BC and, in comparison to estrogen- and progesterone receptor-positive (i.e., hormone receptor-positive, ER+ and PR+, respectively) BC cases have the most aggressive course of the disease and the worst prognosis [2].